Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD

描述（由申请人提供）：本申请要求支持NIDA独立之路奖（K99 ROO），使大卫赫林，博士，发展必要的技能，为独立的研究职业生涯调查药物滥用的治疗。赫林博士拥有独特的经验和专业知识，这将是一个巨大的资产，因为他发展成为一个独立的研究人员。申请人与Kathryn Cunningham博士的博士前培训建立了临床前神经药理学的明确专业知识。值得注意的是，他研究了药理学试剂阻断啮齿动物中精神兴奋剂的行为和生理作用的能力。他对转化研究的兴趣使他在由John Grabowski博士领导的NIDA资助的药物开发单位（P50）获得博士后研究金，在那里，一个精心制定的博士后计划为Herin博士提供了临床研究许多方面的培训。建议的多学科研究计划的指导部分为Herin博士提供了在药物使用障碍临床试验的开发，实施和分析方面获得额外专业知识的机会，包括一项试点研究，该研究考察了苯丙胺治疗可卡因依赖和注意力缺陷多动障碍（ADHD）共病个体的能力。此外，Herin博士将在这些研究的统计分析方面获得丰富的经验，并与正在进行的功能成像研究部门的教师合作。培训将通过教学指导和具有临床试验设计、统计分析和功能成像专业知识的教员的个性化指导提供。这一多学科培训将最终实施一项大规模临床试验，评估苯丙胺治疗ADHD和可卡因依赖共病的疗效。总之，拟议的培训将提供一种独特的、特殊的专门知识，使Herin博士能够作出重大的科学贡献，并在转化药物滥用研究方面开始一个成功的职业生涯。

DESCRIPTION (provided by applicant): This application requests support for a NIDA Pathway to Independence award (K99 ROO) enabling David Herin, Ph.D, to develop the skills necessary for an independent research career investigating pharmacological treatments for substance abuse. Dr. Herin possesses a unique combination of experience and expertise that will be a tremendous asset as he develops into an independent researcher. The applicant's predoctoral training with Dr. Kathryn Cunningham established clear expertise in preclinical neuropharmacology. Notably, he investigated the ability of pharmacotherapeutic agents to block the behavioral and physiological effects of psychostimulants in rodents. His interest in translational research led him to pursue a postdoctoral fellowship in the NIDA-funded medication development unit (P50) led by Dr. John Grabowski, where a well formulated post-doctoral plan provided training for Dr. Herin in many facets of clinical research. The mentored portion of the proposed multidisciplinary research plan provides Dr. Herin with the opportunity to gain additional expertise in development, implementation, and analysis of substance use disorder clinical trials, including a pilot study examining the ability of dextroamphetamine to treat individuals with comorbid cocaine dependence and attention-deficit hyperactivity disorder (ADHD). In addition, Dr. Herin will obtain extensive experience in statistical analysis of these studies, and collaborate with department faculty in ongoing functional imaging studies. Training will be provided via didactic instruction and individualized guidance from faculty members with expertise in clinical trial design, statistical analysis, and functional imaging. This multidisciplinary training will culminate in implementation of a large scale clinical trial assessing the efficacy of dextroamphetamine to treat comorbid ADHD and cocaine dependence. In all, the proposed training will provide a unique, exceptional expertise that will permit Dr. Herin to make significant scientific contributions and embark on a successful career in translational drug abuse research.